Results 101 to 110 of about 4,325,437 (366)
Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer
Molecular Oncology, EarlyView.Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte +10 more
wiley +1 more source
Pharmaceutical Technology in Hospital Pharmacy, 2016 The aim of the study was to evaluate the risk of chemical cross-contamination between preparations of cytotoxic drugs performed in hospital pharmacy. Simulation of handling process errors was performed with two selected tracers, thiamine and retinol to ...
Vazquez Raphael +3 more
doaj +1 more source
Clinical connectivity map for drug repurposing: using laboratory tests to bridge drugs and diseases [PDF]
arXiv, 2020 Drug repurposing has attracted increasing attention from both the pharmaceutical industry and the research community. Many existing computational drug repurposing methods rely on preclinical data (e.g., chemical structures, drug targets), resulting in translational problems for clinical trials.
arxiv
Molecular Oncology, EarlyView.Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed +8 more
wiley +1 more source
Антибиотики и Химиотерапия, 2020 Ingavirin® is low toxic for the MDCK cell culture. The drug concentration of 1000 mcg/ml does not reach the CD50 value. The antiviral activity of Ingavirin® was studied with respect to the influenza virus A/H1N1, including the Remantadin® resistant ...
G. A. Galegov +2 more
doaj
Side-by-Side Comparison of Methods for Environmental Monitoring for Hazardous Drug Contamination. [PDF]
Can J Hosp Pharm, 2023 Hon CY.
europepmc +1 more source
Molecular Oncology, EarlyView.Loss of primary cilia in endothelial cells promotes EndMT and vascular abnormalities in the ovarian tumor microenvironment through EphA2 activation. Using human samples, in vitro models, and endothelial‐specific Kif3a‐knockout mice, we show that primary cilia loss drives the acquisition of cancer‐associated fibroblast‐like phenotypes, thereby ...
Jin Gu Cho +11 more
wiley +1 more source
Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma
Molecular Oncology, EarlyView.GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski +19 more
wiley +1 more source
Drug Recommendation toward Safe Polypharmacy [PDF]
arXiv, 2018 Adverse drug reactions (ADRs) induced from high-order drug-drug interactions (DDIs) due to polypharmacy represent a significant public health problem. In this paper, we formally formulate the to-avoid and safe (with respect to ADRs) drug recommendation problems when multiple drugs have been taken simultaneously.
arxiv
Molecular Oncology, EarlyView.C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald +18 more
wiley +1 more source